ZUBRIN 200 ANTI-INFLAMMATORY TABLETS FOR DOGS

Country: Ավստրալիա

language: անգլերեն

source: APVMA (Australian Pesticides and Veterinary Medicines Authority)

active_ingredient:

TEPOXALIN

MAH:

INTERVET AUSTRALIA PTY LIMITED

INN:

tepoxalin(200mg/Tb)

pharmaceutical_form:

ORAL TABLET

composition:

TEPOXALIN UNGROUPED Active 200.0 mg/Tb

units_in_package:

10 Tablets; 30 Tablets; 60 Tablets

class:

VM - Veterinary Medicine

manufactured_by:

INTERVET AUSTRALIA

therapeutic_group:

DOG | BITCH | CASTRATE | PUPPY

therapeutic_area:

MUSCULOSKELETAL SYSTEM

therapeutic_indication:

ANTI-INFLAMMATORY AGENT | MUSCULOSKELETAL CONDITIONS | ANTIPYRETIC | ARTHRITIS | ARTHROSIS | BONE SORENESS | BRUISING | BURSITIS | EXTERNAL MYOPATHY | INFLAMATION OF SOFT TISSUES AN | INFLAMMATORY RHEUMATIC ARTHRIT | JOINT DISEASE | LIGAMENT SPRAINS | MUSCLE SORENESS | OSTEITIS | OSTEOARTHRITIS | PLATELET ACTIVITY | RHEUMATISM | SPRAINS | STRAINS | TENDON AND LIGAMENT SPRAINS | TENDON SPRAINS | TENDONITIS | TENOSYNOVITIS | TRAUMATIC JOINT AND CONNECTIVE | TRAUMATIC SWELLING

leaflet_short:

Poison schedule: 4; Withholding period: WHP: N/A; Host/pest details: DOG: [ANTI-INFLAMMATORY AGENT, MUSCULOSKELETAL CONDITIONS]; Poison schedule: 4; Withholding period: ; Host/pest details: DOG: [ANTI-INFLAMMATORY AGENT, MUSCULOSKELETAL CONDITIONS]; A non steroidal anti inflammatory for the reduction of inflammation and relief of pain associated with musculoskeletal disorders in dogs.

authorization_status:

Registered

authorization_date:

2023-07-01

SPC

________________________________________________________________________
Schering-Plough Corporation
Global Supply Chain
1095 Morris Avenue
Union, New Jersey 07083-7143
Telephone [phone]
ZUBRIN
 RAPIDLY-DISINTEGRATING TABLETS
(EX000034)
This product is exempt from [Material] Safety Data Sheet requirements.
The following regional exemptions apply:
United States:
According to the OSHA Hazard Communication Standard [29 CFR §
1910.1200 (b) (6) (vii)], an MSDS is
not required for any drug when it is in the solid, final form (_e.g_.
tablets or pills).
European Union:
According to the European Union Commission Directive 2001/58/EC of 27
July 2001, as it relates to
Directive 1999/45/EC [Article 1.5.a], an SDS is not required for
medicinal products in the finished state,
intended for the final user.
Canada:
According to the WHMIS Hazardous Product Act [Part II Controlled
Products 12.b], an MSDS is not
required for any drug within the meaning of the _Food and Drugs Act._
If you have any questions or need assistance, please call
Schering-Plough Animal Health
Corporation at 800- 932-0473. Many Schering-Plough Animal Health
[Material] Safety Data
Sheets may be obtained through the MSDS HelpLine at 800-770-8878 or
from the S-P MSDS
website at www.schering-ploughmsds.com.
Technical inquiries for adverse events in animals for Schering-Plough
Animal Health Products may
be addressed to Schering-Plough Animal Health Technical Services:
For Small Animals and Horses [phone]
For Livestock [phone]
For Poultry [phone]
Sincerely,
Global Safety & Environmental Affairs
Schering-Plough Corporation
Schering-Plough
Global Safety & Environmental Affairs